Spotlight On... India reclears Roche's Avastin for off-label eye sales; Combo of J&J's Zytiga and prednisone tops solo prednisone in PhIII trial; India bans Abbott antibiotic combo; and more...

Earlier this year, India dealt some cards in Roche's ($RHHBY) favor when it suspended off-label eye sales of cancer drug Avastin on reports of vision problems in patients. The Swiss drugmaker has another much pricier option, Lucentis--which boasts a specific eye approval--that it would rather see used in that market. Now, though, India has lifted its alert on the advice of an expert committee, meaning Avastin is once again all clear for the sales. Story from FiercePharmaAsia | More

> In a Phase III trial, a combo of Johnson & Johnson's ($JNJ) Zytiga and prednisone beat out solo prednisone in boosting overall survival for men with early and less aggressive metastatic castration-resistant prostate cancer who had not received chemotherapy. More

> A powerful Abbott Laboratories ($ABT) antibiotic combo is among 344 drug cocktails that Indian health authorities have banned. More

> An Australian law firm has launched a class-action lawsuit on behalf of people who were prescribed antidepressant paroxetine as children and adolescents. More

> Low-priced versions of Gilead's ($GILD) Sovaldi could save the lives of millions of hep C patients in Pakistan, experts say. Report

And Finally... Nature rounds up biotech's "most notorious offenders and their misdeeds" in a new article. Story

Suggested Articles

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.